BSE List Price : ₹980.00

NSE List Price : ₹980.00

subscription

Category	Times
QIBs	186.39x
HNIs	49.8x
Retail	12.96x
Total : 70.26x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	1	18	₹14,526
Retail Maximum	13	234	₹188,838
S-HNI Minimum	14	252	₹203,364
S-HNI Maximum	68	1,224	₹987,768
B-HNI Minimum	69	1,242	₹1,002,294

About the Company

Diagnostics Limited was subsequently converted into a public limited company in January 2025 and adopted its current name.

Molbio Diagnostics is a technology-driven point-of-care (POC) molecular diagnostics company engaged in developing rapid, reliable, and affordable diagnostic solutions for infectious as well as non-communicable diseases. The company focuses on expanding access to high-quality healthcare by enabling decentralized diagnostic testing, especially in underserved and resource-constrained regions.

Its flagship product, Truenat, is a portable, battery-powered PCR-based molecular diagnostics platform that delivers test results in less than an hour. Developed over 13 years of extensive research and development, Truenat has been certified by the Indian Council of Medical Research (ICMR) for tuberculosis testing and is among only two rapid molecular diagnostic platforms worldwide endorsed by the World Health Organization (WHO) for the initial detection of tuberculosis and rifampicin resistance. In addition to tuberculosis, the platform is capable of detecting diseases such as COVID-19, Hepatitis B & C, HIV, and Human Papillomavirus (HPV), and its proprietary technology is protected by patents across more than 100 countries.

The company's research and development operations are undertaken through its wholly owned subsidiary, Bigtec Private Limited, headquartered in Bengaluru, Karnataka. Bigtec is engaged in the design and development of advanced point-of-care diagnostic platforms and is supported by a multidisciplinary team of professionals specializing in biology, chemistry, software, and engineering, along with state-of-the-art research infrastructure.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2024	₹840.66	₹657.83	₹83.54	₹1221.06
2025	₹1027.94	₹820.41	₹138.58	₹1461.56
2026	₹1455.17	₹1221.35	₹164.14	₹2148.42

Company Promoter

Chandrasekhar Bhaskaran Nair

Exxora Trading LLP

Sangeetha Sriram

Shiva Sriram

Sowmya Sriram

Sriram Natarajan

Know before investing

• • Strengths

  Strong Presence in Molecular Diagnostics: Well-positioned to capitalize on the expanding molecular diagnostics market through its Truenat point-of-care testing platform.

  Proprietary Point-of-Care Technology: Successfully developed and commercialized the Truenat portable PCR-based molecular diagnostics platform, enabling rapid and accurate testing for multiple diseases.

• • Risks

  R&D and Regulatory Approval Risk: The company's growth depends on successful research and development activities and timely regulatory approvals for new diagnostic tests. Any delays or failure in product development or approvals could adversely affect future growth.

  Demand Planning and Inventory Management Risk: Ineffective demand forecasting or inventory management could result in excess stock or product shortages, which may negatively impact operational efficiency and profitability.

Objects of the Issue & Utilisation of proceeds

Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space.

Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and.

General corporate purposes.

Company  Address

Molbio Diagnostics Ltd.
Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete
South Goa, Goa, 403722
Phone: +91 8326724888
Email: investors@molbiodiagnostics.com
Website: http://www.molbiodiagnostics.com/

IPO Registrar

Kfin Technologies Ltd.
Phone: 040-79615565
Email: molbio.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/